ASCO GI 2023 Conference Coverage


 

ASCO GI 2023 Results From a Phase 1a/1b Study: Botensilimab, a Novel Innate/Adaptive Immune Activator, + Balstilimab in Metastatic Heavily Pretreated Microsatellite Stable CRC

157 views
January 25, 2023
Comments 0
Login to view comments. Click here to Login